Market capitalization | $6.57m |
Enterprise Value | $-17.93m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.58 |
P/B ratio (TTM) P/B ratio | 0.39 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-37.22m |
Free Cash Flow (TTM) Free Cash Flow | $-30.72m |
Cash position | $24.50m |
As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.
3 Analysts have issued a Forte Biosciences Inc forecast:
3 Analysts have issued a Forte Biosciences Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.03 -0.03 |
-
|
|
EBITDA | -37 -37 |
53%
53%
|
EBIT (Operating Income) EBIT | -37 -37 |
53%
53%
|
Net Profit | -36 -36 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Forte Biosciences, Inc. engages in the development of biopharmaceutical products. It is a clinical stage dermatology company focuses in the treatment of inflammatory skin diseases. It offers FB-401, a live bio-therapeutic product. The company was founded by Paul A. Wagner in 2017 and is headquartered in Torrance, CA.
Head office | United States |
CEO | Paul Wagner |
Employees | 9 |
Founded | 2017 |
Website | www.fortebiorx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.